Bioorthogonal Equipping CAR-T Cells with Hyaluronidase and Checkpoint Blocking Antibody for Enhanced Solid Tumor Immunotherapy.

Bioorthogonal Equipping CAR-T Cells with Hyaluronidase and Checkpoint Blocking Antibody for Enhanced Solid Tumor Immunotherapy.
复制标题

生物正交为 CAR-T 细胞配备透明质酸酶和检查点阻断抗体,用于增强实体瘤免疫治疗

DOI:
10.1021/acscentsci.2c00163
复制
发表时间:
2022-05-25
影响因子:
18.2
通讯作者:
Lian, Zhexiong
Lian, Zhexiong
中科院分区:
化学1区
文献类型:
--
作者:
Zhao, Yangyang;Dong, Yansong;Yang, Shuhan;Tu, Yalan;Wang, Chengbo;Li, Jun;Yuan, Youyong;Lian, Zhexiong

文献摘要

参考文献

被引文献

相似文献

利用嵌合抗原受体重定向T(CAR - T)细胞的过继性细胞疗法在血液系统恶性肿瘤治疗中展现出了令人瞩目的疗效。相比之下,CAR - T疗法在治疗实体瘤方面的疗效仍然欠佳,这在很大程度上归因于其难以有效穿透实体瘤以及实体瘤存在免疫抑制性的肿瘤微环境。在此,我们通过高效且生物相容性良好的生物正交点击化学方法,在CAR - T细胞表面构建了透明质酸酶(HAase)和免疫检查点阻断抗体α - PDL1,以提高其对实体瘤的治疗效果。体外浸润实验和体内生物分布研究表明,修饰后的透明质酸酶可降解透明质酸并破坏肿瘤细胞外基质,使CAR - T细胞能够深入渗透到实体瘤中。此外,体外细胞毒性研究显示,经α - PDL1修饰的细胞比传统CAR - T细胞具有更强的抗肿瘤活性。重要的是,经HAase和α - PDL1改造的CAR - T细胞在两种实体瘤模型中均显示出更好的治疗效果,且未引起明显的全身性副作用。在这项研究中,我们提供了一种简单、高效且生物安全性良好的化学策略,对传统CAR - T细胞进行改造,以增强其对实体瘤的治疗效果。该策略可推广至其他过继性细胞免疫疗法,具有巨大的临床应用潜力。 通过生物正交点击化学,我们在CAR - T细胞表面构建了可降解肿瘤细胞外基质的透明质酸酶和免疫检查点阻断抗体α - PDL1,以改善实体瘤的治疗效果。
Adoptive cellular therapy utilizing chimeric antigen receptor redirected T (CAR-T) cells has shown impressive therapeutic effects on hematological malignancies. In contrast, the efficacy of CAR-T therapies in treating solid tumors is still poor, which is largely due to inefficient penetration into solid tumors and the immunosuppressive tumor microenvironment. Herein, we engineered hyaluronidase (HAase) and the checkpoint blocking antibody α-PDL1 on the CAR-T cell surface via highly efficient and biocompatible bioorthogonal click chemistry to improve their therapeutic effects on solid tumors. The modified HAase degrades hyaluronic acid and destroys the tumor extracellular matrix, allowing CAR-T cells to penetrate deeply into solid tumors, as evidenced by in vitro infiltration experiments and in vivo biodistribution studies. In addition, in vitro cytotoxicity studies showed stronger antitumor activity of α-PDL1-decorated cells than traditional CAR-T cells. Importantly, HAase- and α-PDL1-engineered CAR-T cells showed better therapeutic efficacy on two solid tumor models and did not cause significant systemic side effects. In this work, we provide a simple, efficient, and biologically safe chemical strategy to engineer traditional CAR-T cells for enhanced therapeutic efficacy on solid tumors, which can be extended to other adoptive cellular immunotherapies and holds great potential for clinical application. With bioorthogonal click chemistry, we engineered CAR-T cells with the tumor extracellular matrix degrading enzyme hyaluronidase and the checkpoint blocking antibody α-PDL1 on the surface to improve solid tumor treatment.
Marsdenia tenacissima 提取物抑制 A20 小鼠淋巴瘤的肿瘤生长和血管生成
DOI: 10.3892/ol.2017.5831
发表时间: 2017-05
期刊: Oncology letters
影响因子: 2.9
作者:
Dai X;Ji Y;Jiang P;Sun X
通讯作者: Sun X
DOI: 10.1038/nrc3239
发表时间: 2012-03-22
期刊: Nature reviews. Cancer
影响因子: --
作者:
Pardoll DM
通讯作者: Pardoll DM
T 细胞和肿瘤微环境之间的 IFN-gamma/PD-L1 轴:神经胶质瘤抗 PD-1/PD-L1 治疗的提示。
DOI: 10.1186/s12974-018-1330-2
发表时间: 2018-10-17
影响因子: 9.3
作者:
Qian J;Wang C;Wang B;Yang J;Wang Y;Luo F;Xu J;Zhao C;Liu R;Chu Y
通讯作者: Chu Y
DOI: 10.1038/s41591-018-0014-x
发表时间: 2018-05
期刊: Nature medicine
影响因子: 82.9
作者:
Binnewies M;Roberts EW;Kersten K;Chan V;Fearon DF;Merad M;Coussens LM;Gabrilovich DI;Ostrand-Rosenberg S;Hedrick CC;Vonderheide RH;Pittet MJ;Jain RK;Zou W;Howcroft TK;Woodhouse EC;Weinberg RA;Krummel MF
通讯作者: Krummel MF
DOI: 10.1080/2162402x.2018.1509819
发表时间: 2018
期刊: Oncoimmunology
影响因子: 7.2
作者:
Oyer JL;Gitto SB;Altomare DA;Copik AJ
通讯作者: Copik AJ